Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Sales | 27,116,000 | 27,281,000 | 27,305,000 | 24,689,000 | 22,449,000 |
| Cost of Goods | 6,498,000 | 5,657,000 | 6,601,000 | 4,572,000 | 4,675,000 |
| Gross Profit | 20,618,000 | 21,624,000 | 20,704,000 | 20,117,000 | 17,774,000 |
| Operating Expenses | 13,013,000 | 14,294,000 | 10,786,000 | 16,046,000 | 13,487,000 |
| Operating Income | 7,605,000 | 7,330,000 | 9,918,000 | 4,071,000 | 4,287,000 |
| Interest Expense | 944,000 | 935,000 | 1,001,000 | 984,000 | 995,000 |
| Other Income | 198,000 | -581,000 | -639,000 | -1,418,000 | 1,868,000 |
| Pre-tax Income | 6,859,000 | 5,814,000 | 8,278,000 | 1,669,000 | 5,160,000 |
| Income Tax | 1,247,000 | 1,248,000 | 2,077,000 | 1,580,000 | -204,000 |
| Net Income Continuous | 5,612,000 | 4,566,000 | 6,201,000 | 89,000 | 5,364,000 |
| Minority Interests | -52,000 | -26,000 | -24,000 | -34,000 | -22,000 |
| Net Income | $5,665,000 | $4,592,000 | $6,225,000 | $123,000 | $5,386,000 |
| EPS Basic Total Ops | 4.54 | 3.66 | 4.96 | 0.10 | 4.24 |
| EPS Basic Continuous Ops | 4.50 | 3.64 | 4.94 | 0.07 | 4.22 |
| EPS Diluted Total Ops | 4.50 | 3.64 | 4.93 | 0.10 | 4.22 |
| EPS Diluted Continuous Ops | 4.46 | 3.62 | 4.91 | 0.07 | 4.20 |
| EPS Diluted Before Non-Recurring Items | 6.72 | 7.26 | 7.28 | 7.09 | 6.14 |
| EBITDA(a) | $10,298,000 | $9,433,000 | $11,968,000 | $5,551,000 | $5,691,000 |